GlassScriptPhysician profile
Kitra C Nichols
NPI 1467893891
$9,130.83
in general payments reported to CMS, 2019-2025
63 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,495 · 2023: $2,541 · 2024: $2,685 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,635.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $913.27 | 2022-2025 | |
| Janssen Biotech, INC. | $608.13 | 2022-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $596.74 | 2022-2025 | Enhertu, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $552.05 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $391.50 | 2022-2025 | |
| Lilly USA, LLC | $359.64 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $359.24 | 2022-2025 | Injectafer, Enhertu, Datroway |
| Celgene Corporation | $296.09 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $279.41 | 2022-2025 | Tecentriq, Polivy, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $278.13 | 2022-2025 | Fruzaqla, Alunbrig, Exkivity |
| Glaxosmithkline, LLC. | $231.15 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $181.37 | 2022-2025 | |
| Seagen INC. | $181.00 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Astellas Pharma US INC | $178.61 | 2022-2025 | Xtandi, Xospata, Padcev |
| Incyte Corporation | $175.72 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $174.06 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $155.02 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Puma Biotechnology, INC. | $150.11 | 2022-2025 | |
| Genmab U.S., INC. | $148.77 | 2022-2025 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $146.91 | 2022-2025 | Fotivda |
| Eisai INC. | $142.54 | 2022-2024 | |
| Emd Serono, INC. | $142.52 | 2023-2025 | Bavencio, Tepmetko |
| Exelixis INC. | $132.30 | 2022-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $131.87 | 2022-2025 | |
| Taiho Oncology, INC. | $130.15 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $129.35 | 2022-2025 | Xpovio |
| Sumitomo Pharma America, INC. | $117.69 | 2023-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $108.91 | 2022-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $108.80 | 2022-2024 | Somatuline Depot, Onivyde |
| Abbvie INC. | $105.27 | 2022-2025 | |
| Array Biopharma INC | $98.63 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Servier Pharmaceuticals LLC | $93.45 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $89.87 | 2023 | Qinlock |
| Mirati Therapeutics, INC. | $86.16 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $80.92 | 2022-2024 | Ultomiris |
| Spectrum Pharmaceuticals INC. | $79.20 | 2023-2024 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.61 | 2025 | |
| Blueprint Medicines Corporation | $73.25 | 2022-2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $72.26 | 2023-2025 | Opdivo, Opdualag, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $72.19 | 2022-2024 | |
| Beigene USA, INC. | $65.36 | 2022-2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $62.97 | 2022-2024 | Xarelto |
| Beone Medicines USA, INC. | $55.68 | 2025 | Brukinsa, Tevimbra |
| Immunocore Limited | $47.56 | 2025 | Kimmtrak |
| Macrogenics, INC. | $47.43 | 2022-2023 | |
| Kyowa Kirin, INC. | $36.29 | 2023-2024 | Poteligeo |
| Sobi, INC | $33.79 | 2023-2025 | |
| Eagle Pharmaceuticals, INC. | $32.25 | 2022-2024 | |
| Morphosys, US INC. | $31.75 | 2022 | |
| Springworks Therapeutics, INC. | $29.82 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $27.34 | 2022-2023 | Vonjo |
| Genentech, INC. | $25.79 | 2024 | Lunsumio, Columvi |
| Stemline Therapeutics INC. | $25.74 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $24.14 | 2025 | Zoladex |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $23.45 | 2024 | Besremi |
| Verastem, INC. | $19.76 | 2025 | Avmapki Fakzynja Co-Pack |
| Myovant Sciences INC. | $17.19 | 2022 | |
| G1 Therapeutics, INC. | $17.12 | 2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $15.14 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.79 | 2023 | Monoferric |
| Coherus Oncology, INC. | $14.31 | 2025 | Loqtorzi |
| Helsinn Therapeutics (U.S.), INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitra Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.